Viral Vectors And Plasmid DNA Manufacturing Market Is Gaining Major Traction With Oxford Biomedica Plc Entering Into A 3-Year Agreement With Boehringer Ingelheim For The Manufacture And Supply Of Various Types Of Viral Vectors

 

Viral Vectors are proteins that have been discovered to be essential for the spread of various viruses and infectious agents. These proteins can cause serious health risks if they are improperly introduced or if a wrong agent is used to fight them off. Viral vectors have often been used in various gene therapy procedures with the ultimate objective of curing various ailments in the biological fields of neurology, gene therapy, cancer, and metabolic disorder. Clinical studies regarding viral vectors remain one of the key factors in the manufacturing of viral vectors. Plasmids are used to deliver DNA contain genes for antibiotic resistance. In fact, scientists have developed many uses of plasmids and created software to record the DNA sequences of plasmids for applications in various techniques. Thus, such continuous R&D activities can potentially stimulate growth of the viral vectors and plasmid DNA manufacturing market.

Recently, in April 2021, Oxford Biomedica plc entered into a new three-year Development & Supply Agreement (DSA) with Boehringer Ingelheim for the manufacture and supply of various types of viral vectors.

The cases of genetic disorders such as Down syndrome, Cystic Fibrosis, Huntington’s disease, and hemophilia have gone up over the years worldwide. As per the Cystic Fibrosis Foundation (CFF), over 70,000 people across the globe live with cystic fibrosis with around 1,000 new cases diagnosed each year. As per the Centers for Disease Control and Prevention (CDC), each year around 6,000 babies are born with Down syndrome in the U.S. Viral vectors are crucial in the diagnosis of these types of genetic disorders. Thus, such factors can stimulate growth of the viral vectors and plasmid DNA manufacturing market.

Due to the alarming rate at which these viruses get resistant to medicines, it is very important to use appropriate gene therapy procedures for patients who are prone to receiving infections from these deadly diseases. The most dangerous aspect of these viral vectors is that a large number of people may get exposed to the virus if the medical practitioner uses the wrong type of approach in treating patients with neurological disorders. That being said, one of the major challenges in the adoption of viral vectors is the high cost of gene therapies. The cost of production is weighed against the value of a life saved or improved quality of life of a specific time period. Besides, there are many hurdles related to viral vector manufacturing capacity that can potentially inhibit growth of the viral vectors and plasmid DNA manufacturing market.

Gene therapy applications based on viral vectors are also very helpful in fighting against other transgene-associated diseases. It is necessary for professionals to be more careful in applying these applications in order to prevent untoward events such as side effects. As far as regional impact is concerned, developed countries in North America such as the U.S. seem to be gaining robust traction in the regional viral vectors and plasmid DNA manufacturing market. This is typically due to frequent product approvals from the U.S. Food and Drug Administration (FDA).